Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Bonothyrk6 residuesAEDLRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: A-21, Peptide Complex A-21, Parathyroid Peptide Bioregulator
Four amino acids from a calf parathyroid gland, swallowed as a capsule for 30 days, then nothing for months. Bonothyrk (Peptide Complex A-21) is a Khavinson bioregulator targeting parathyroid chief cells through epigenetic gene expression changes. The only clinical observation comes from 33 perimenopausal women at the St. Petersburg Institute of Bioregulation and Gerontology, where 40 mg/day for 30 days improved bone mineral density markers versus controls. That study has no PMID, no journal publication, and no independent replication. Users in European longevity circles report reduced muscle cramping within two weeks. Bone outcomes require DEXA verification.
Thirty-three women and zero PubMed results. That's the full clinical evidence base for Bonothyrk, a bovine-derived parathyroid peptide bioregulator also known as Peptide Complex A-21. Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology developed this product. It contains short-chain polypeptides (2 to 7 amino acid residues) extracted from the parathyroid glands of young cattle. The proposed mechanism: peptide fragments cross cell membranes, enter parathyroid chief cell nuclei, and bind DNA promoter regions. This theoretically modulates gene expression controlling parathyroid hormone (PTH) synthesis and calcium-sensing receptor (CaSR) sensitivity. Users take 10 mg capsules orally for 30-day courses, repeated two to three times per year. The carry-forward effect draws the most interest; gene expression changes are thought to persist three to six months after stopping. Community experience on Longecity (thread 111763) and vendor review sections tracks fewer than 50 identifiable reports. Reduced muscle cramp frequency is the most consistent subjective outcome. The sole clinical observation tracked 33 perimenopausal women (ages 47 to 56) receiving 40 mg/day for 30 days. BMD parameters improved compared to controls. This study was never published in a peer-reviewed journal and carries no PMID. Broader Khavinson bioregulator research has indexed support [1], but those papers don't validate parathyroid-specific claims. Khavinson died in 2024, ending primary institutional output. Objective benefit assessment requires DEXA scanning and lab monitoring.
The proposed mechanism sits entirely within Khavinson's bioregulatory framework. Short-chain peptide fragments (2 to 7 amino acid residues) derived from bovine parathyroid tissue absorb orally and theoretically reach parathyroid chief cells via intestinal peptide transporters. Once inside the cell, these fragments cross the nuclear membrane and bind to complementary sequences in gene promoter regions. This modulates RNA polymerase activity, triggering transcription of proteins involved in PTH synthesis and secretion. At the epigenetic level, the peptides may alter DNA methylation patterns. The proposed result is a shift toward younger, more functional gene expression in parathyroid tissue. The downstream target is the calcium-sensing receptor (CaSR). CaSR sensitivity declines with age, meaning parathyroid cells respond less accurately to blood calcium fluctuations. Restored CaSR function would mean better-regulated PTH release. PTH governs three calcium pathways simultaneously: renal reabsorption, skeletal mobilization, and intestinal absorption through vitamin D activation. None of this has been confirmed specifically for Bonothyrk. The mechanism is extrapolated from general Khavinson peptide research on peptide-DNA interactions [3]. No Western lab has independently verified parathyroid-specific epigenetic effects from oral administration of this complex.
No PubMed-indexed studies exist specifically on Bonothyrk. The sole cited clinical observation (33 perimenopausal women, 40 mg/day × 30 days, measurable BMD improvement) is unpublished Russian institute data circulated as vendor copy: no PMID, journal, or independent verification. Broader Khavinson class studies (PMIDs 23734519, 24003726) support the general bioregulation framework but do not validate parathyroid-specific effects. No independent Western replication exists. Khavinson died 2024, ending primary institutional output.
Khavinson et al. (unpublished/unindexed): 33 perimenopausal women aged 47–56, 40 mg/day × 30 days: improved BMD parameters vs. controls. No PMID. Broader class reference: PMID 23734519 (Peptide bioregulators geroprotectors Communication 1, 2013).
Zero independent replication; all evidence originates from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson group); primary clinical study is not peer-reviewed in any indexed journal; no English-language RCT; no PK data specific to this compound; mechanism remains theoretical.
Minimal community presence. Usage concentrated in European and Russian longevity/biohacker circles via Longecity forum and vendor review sections. Zero Reddit threads indexed. Most users cannot verify bone outcomes without DEXA. Carry-forward effect (3–6 months post-course) is the most cited practical advantage.
Community-reported benefits (muscle cramp reduction, bone support) align with the theoretical Khavinson parathyroid mechanism. Neither side contradicts the other. However, both evidence streams are weak: science is limited to one unpublished institute observation; community volume is too low for reliable sentiment analysis. Alignment reflects absence of contradiction, not corroboration by independent data.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 10mg | 2x Daily |
| Aggressive | 20mg | 2x Daily |
Each capsule contains 10 mg of the parathyroid peptide complex (A-21). No reconstitution, no syringes, no bacteriostatic water. Oral capsule. The 20-cap box provides one 10-day conservative course at 20 mg/day (2 capsules). The 60-cap box covers a full 30-day course at that same dose. Running the aggressive 40 mg/day protocol burns 4 capsules daily; you'll need two 60-cap boxes for one course. Take capsules with food. Fasted dosing is the main cause of GI complaints. Morning and midday with meals; skip the evening dose. You won't feel this working. The mechanism is epigenetic gene expression modulation in parathyroid cells. There's no acute signal, no mood change, no energy shift. Muscle cramp reduction around week 2 is the earliest subjective marker. Bone outcomes require DEXA imaging at 6 months. Don't bump the dose because nothing "happened" by day 10. Check serum calcium before starting. If it's above 10.2 mg/dL, don't start. Buy from CosmicNootropic, RuPharma, or QiSupplements; avoid Amazon and eBay listings.
Standard Khavinson protocol: 30-day course of daily oral capsules, repeated 2-3 times per year with 4-6 month intervals between courses. Some practitioners recommend an initial loading phase of two courses with a 1-month break in between for individuals with significant parathyroid or calcium metabolism concerns.
Cycling follows the Khavinson epigenetic model: short-chain peptide fractions (2–7 AA) interact with parathyroid cell DNA promoter regions during the active 30-day course, triggering sustained gene expression changes that persist 3–6 months after stopping without continued dosing. The 4–6 month off-period is not for receptor recovery (no receptor downregulation is claimed in this mechanism) but to allow the full carry-forward epigenetic effect to run its course before retreating to refresh or amplify changes. Continuous daily use has no established safety data and is not recommended in any Khavinson institute documentation.
Or use the universal Peptide Calculator for any peptide.
Expected: Parathyroid gland support and calcium metabolism normalization; muscle cramp reduction is the most detectable subjective marker. Objective outcomes require DEXA scan at 6-month mark.
Monitor: Check serum calcium (total + ionized) before starting first course. Recheck at course end. Monitor intact PTH and serum phosphorus at 6-month interval.
Get baseline labs before your first course: serum calcium (total and ionized), intact PTH, serum phosphorus. Rule out pre-existing hypercalcemia.
Beginner: 1 capsule (10 mg) once daily. Standard: 2 capsules (20 mg) once daily with breakfast. Aggressive: 2 capsules (20 mg) twice daily, morning and midday, each with a meal (40 mg/day total).
Don't crush or open them. Always take with food.
Avoid evening dosing.
Don't skip days. Don't extend past 30 days at the aggressive dose.
Compare to baseline.
Wait four to six months before the next course. The carry-forward effect sustains gene expression changes during this gap.
Get a DEXA scan at baseline and at six months.
Sublingual version: 5 to 6 drops held under the tongue for 10 to 15 minutes, 3 to 4 times daily. Total daily dose is 7.5 to 14 mg (lower than oral capsules). No bioavailability comparison study exists.
Store in original blister packaging at 15 to 25 degrees Celsius, away from moisture and light.
5–6 drops (~2.5–3.5 mg/dose) held sublingually for 10–15 minutes, 3–4×/day = ~7.5–14 mg total daily dose: substantially lower than oral capsule protocol (20–40 mg/day)
Bypasses first-pass hepatic metabolism and gut acid degradation, theoretically improving bioavailability per unit dose. However, total daily peptide exposure is lower than the capsule protocol. Practical advantage for users with GI sensitivity or swallowing difficulty. No head-to-head bioavailability study exists.
Classic Khavinson longevity combination: pineal bioregulator (A-8) paired with parathyroid bioregulator (A-21); frequently co-administered in Russian Institute protocols for multi-gland epigenetic aging support
Thymic immune bioregulator (A-6 complex); combined with Bonothyrk in Longecity longevity stacks for immune + calcium homeostasis support during the same 30-day course window
Adrenal cortex bioregulator; listed in relatedPeptideIds and co-administered in broader Khavinson multi-gland anti-aging panels targeting multiple endocrine organs simultaneously
Neurological/pineal bioregulator listed in relatedPeptideIds; included in comprehensive Khavinson protocol stacks alongside parathyroid support for systemic aging intervention
Additive effect on serum calcium: Bonothyrk stimulates PTH-mediated calcium mobilization; concurrent high-dose calcium supplementation may push serum calcium above reference range
High-dose vitamin D independently raises serum calcium via intestinal absorption; combined with parathyroid stimulation, hypercalcemia risk increases meaningfully
Thiazides reduce urinary calcium excretion, raising serum calcium independently; additive effect with parathyroid stimulation creates hypercalcemia risk
Lithium directly stimulates PTH secretion and causes secondary hyperparathyroidism as a known adverse effect; concurrent use with a parathyroid bioregulator creates unpredictable PTH/calcium dysregulation
Do not combinePricing updated 2026-04-09
The biggest safety concern with Bonothyrk is not a specific adverse event. It's the near-total absence of controlled safety data. No English-language peer-reviewed study has evaluated this product's safety profile. Everything below comes from Russian clinical observations and a community sample of fewer than 50 identifiable user reports. Bovine origin introduces a theoretical prion contamination risk. Bonothyrk is derived from the parathyroid glands of young cattle. Any bovine glandular product carries this consideration. No cases of prion disease have been linked to Bonothyrk use. The risk is theoretical but not zero, and it cannot be formally quantified without epidemiological surveillance that doesn't exist for this product. Individuals with formal prion risk factors should consult a physician. Hypercalcemia is the most clinically actionable risk. Bonothyrk stimulates parathyroid function and PTH-mediated calcium mobilization. Serum calcium can rise above the reference range (above 10.2 mg/dL total). Symptoms: fatigue, nausea, excessive urination, constipation. In severe cases, cardiac arrhythmia. This risk compounds with concurrent calcium supplements above 1,000 mg/day, vitamin D above 4,000 IU/day, thiazide diuretics, or lithium. If serum calcium rises above the normal range (upper limit approximately 10.2 mg/dL), stop dosing and retest in one week. Lithium users face a specific danger. Lithium directly stimulates PTH secretion and causes secondary hyperparathyroidism as a known adverse effect. Adding a parathyroid bioregulator creates unpredictable PTH and calcium dysregulation. This combination should be avoided. Gastrointestinal discomfort is the most commonly reported side effect. Nausea and stomach upset occur mainly when capsules are taken without food. At 40 mg/day, split across morning and midday meals. Symptoms typically resolve by day 3 to 5. Allergic reactions are possible given the bovine protein content. Headache and mild dizziness have been reported occasionally but without frequency data. For kidney stone formers, PTH stimulation increases urinary calcium excretion. A baseline 24-hour urine calcium test is recommended. If urinary calcium exceeds 300 mg/24h (men) or 250 mg/24h (women), the risk-benefit calculation changes. Pregnancy and breastfeeding are hard contraindications. No safety data exists. Children under 14 should not use this product. Post-surgical parathyroid removal is a hard contraindication; there is no tissue for Bonothyrk to act on. Individuals with primary hyperparathyroidism or severe renal impairment affecting calcium excretion should not use Bonothyrk. Check serum calcium before your first course. That single lab draw is the most important safety step.
Verify Bonothyrk dosing and safety with a second opinion
Bovine-derived glandular peptide complex manufactured primarily in Russia without confirmed Western GMP certification (no FDA, EMA, or TGA oversight). Theoretical prion contamination risk inherent to bovine glandular products (not observed in practice). Supply chain inconsistency: RuPharma frequently lists as out of stock. Product appears on Amazon, eBay, and Walmart third-party marketplaces where chain-of-custody and product authenticity cannot be verified.
| Test | When | Target |
|---|---|---|
| Serum calcium (total and ionized) | Before starting first course (baseline); at day 30 (course end); every 6 months during ongoing cycling | Total calcium: 8.5–10.2 mg/dL | Ionized calcium: 4.6–5.3 mg/dL |
| Intact PTH (parathyroid hormone) | Before starting first course; at day 30 (course end); at 6 months (mid-off period) | 10–65 pg/mL (intact PTH); interpretation requires clinical context and baseline comparison |
| Serum phosphorus | With each calcium/PTH panel | 2.5–4.5 mg/dL |
| DEXA scan (bone mineral density) | Baseline before first course; repeat at 6 months (after 1–2 complete courses) | — |
| 24-hour urine calcium | Before starting, for any user with a personal or family history of kidney stones | <300 mg/24h (men) | <250 mg/24h (women) |
Primary safety biomarker: Bonothyrk stimulates parathyroid function. Baseline hypercalcemia is a hard contraindication. Confirms serum calcium remains within reference range.
Primary efficacy biomarker: if Bonothyrk is working as theorized, PTH regulation should normalize toward reference range. Baseline establishes whether meaningful parathyroid dysfunction is present.
PTH regulates phosphorus excretion inversely; tracking phosphorus provides a cross-check on calcium-phosphorus homeostasis and helps characterize the direction of any imbalance.
Objective measurement of the primary claimed benefit. The only reliable way to verify whether BMD outcomes are occurring. Without imaging, bone effects cannot be self-assessed.
PTH stimulation increases urinary calcium excretion; stone formers are at elevated risk of new stone formation if urinary calcium rises. Establishes baseline and informs decision to proceed.
No noticeable effects expected. The peptide complex begins interacting with parathyroid cells at the gene expression level. Some users report reduced frequency of muscle cramps.
Subtle improvements in calcium-related symptoms may begin. Reduced muscle spasms and cramping have been reported anecdotally. Gene expression changes are believed to be underway.
Full course effects should be building. Clinical observations suggest measurable improvements in bone mineral density markers by the end of a 30-day course, though individual results vary widely.
Benefits are thought to persist for several months after completing a course due to sustained gene expression changes in parathyroid tissue. This is the rationale for the 4-6 month gap between courses.
Cumulative benefits with repeated courses are reported in Khavinson bioregulator literature. Bone density and calcium metabolism parameters may show progressive improvement across multiple treatment cycles.
Days 1 to 7, Course initiation. Nothing perceptible happens. Peptide fractions absorb through intestinal peptide transporters and theoretically reach parathyroid chief cells. No biochemical signal is expected. Some users get mild nausea or bloating in days 1 through 3 when taking capsules without food. Taking them with a meal fixes that. Days 8 to 21, Accumulation phase. Epigenetic changes in parathyroid gene expression are theorized to build through DNA promoter binding. Labs would be the only way to detect it. A subset of users with calcium-related muscle cramps report reduced frequency starting around week 2. Most people notice nothing. Days 22 to 30, Course completion. The 33-woman Khavinson observation showed measurable BMD marker improvements at day 30 versus controls. Muscle cramp reduction is the most consistently reported outcome. PTH regulation is theorized to be at least partially restored by course end. Months 1 to 4 post-course, Carry-forward period. You stop dosing but effects don't stop. Khavinson's model predicts sustained gene expression changes in parathyroid tissue for 3 to 6 months. No crash effect reported. Calcium-related symptoms stay suppressed. Labs may continue showing calcium normalization. Six months and beyond, Repeat courses. Experienced users run 2 to 3 annual courses. The broader Khavinson literature claims progressive improvement across treatment cycles. No independently verified data exists on cumulative Bonothyrk-specific outcomes. DEXA trends over 1 to 2 years are the only objective measure.
Peptide fractions absorb via intestinal peptide transporters and are theorized to reach parathyroid chief cells, interacting with gene promoter regions. No macroscopic effect or measurable biochemical signal expected at this stage.
No subjective changes reported in this window. Mild GI adjustment (nausea, bloating) in a minority of users in days 1–3 when taken without food.
Epigenetic changes to parathyroid cell gene expression are theorized to accumulate via DNA promoter binding and RNA polymerase modulation. No measurable signal without serial intact PTH or calcium labs.
A subset of users with calcium-related muscle cramps report reduced frequency beginning around week 2. The majority report no perceptible change in this window.
The sole cited clinical observation (Khavinson, 33 perimenopausal women) showed measurable BMD marker improvements at day 30 vs. controls. PTH regulation theorized to be at least partially restored.
Reduction in muscle cramp frequency is the most consistently noted subjective outcome. Some users report improved musculoskeletal stability, though this is subjective and unverifiable without imaging.
Khavinson model predicts sustained gene expression changes in parathyroid tissue for 3–6 months post-course, allowing PTH regulation to remain improved without continued dosing.
No crash effect reported upon stopping. Calcium-related symptoms remain suppressed during this period for most users. Labs may continue to show calcium normalization.
Khavinson's broader bioregulator literature claims progressive BMD and calcium metabolism improvement across 2–3 annual courses. No independently verified data on cumulative Bonothyrk-specific outcomes.
Experienced Khavinson bioregulator users run 2–3 annual courses and report sustained benefits with subsequent courses; primary self-assessment markers are absence of calcium-related symptoms and DEXA trends over 1–2 years.
Source: Estimated from general polypeptide fraction kinetics; no Bonothyrk-specific PK studies published (Khavinson & Anisimov, 2010)
Loading the interactive decay curve.
Bonothyrk has no FDA, EMA, or TGA approval. It is classified as a parapharmaceutical in Russia and several CIS countries, manufactured under the NPCRIZ label associated with the Khavinson Institute. No Western regulatory body has reviewed it. In the United States, Bonothyrk is sold as a research compound or dietary supplement. It is not scheduled or controlled. Importing for personal use generally works but customs seizure is possible. No WADA status has been established. Supply chain integrity matters. The product appears on Amazon, eBay, and Walmart third-party marketplaces where authenticity cannot be verified. Established vendors with traceable sourcing include CosmicNootropic, RuPharma, QiSupplements, iPept, and Vita-Stream. This content is for informational purposes only. It does not constitute medical advice. Bonothyrk is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before starting any peptide protocol.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
